8-KEarnings & ResultsRegulation FDExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Feb 2, 2024)

Filed February 2, 2024For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb Company (BMY) filed an 8-K on February 2, 2024, to announce its financial results for the fourth quarter and full year of 2023. The filing primarily includes the press release detailing these results (Exhibit 99.1) and a supporting presentation (Exhibit 99.2), both of which were made available on February 2, 2024. These documents provide key financial and operational updates for investors to assess the company's performance. The company is utilizing this 8-K filing to furnish the earnings press release and presentation materials, which contain both GAAP and non-GAAP financial information. Investors are directed to the press release for reconciliations between these measures. The filing itself does not introduce new material events beyond the financial results announcement, but investors should review the furnished exhibits for a comprehensive understanding of BMY's 2023 performance and outlook.

Key Highlights

  • 1BMY announced its Q4 and Full Year 2023 financial results on February 2, 2024, via an earnings press release.
  • 2The 8-K filing includes the full earnings press release (Exhibit 99.1) and a presentation (Exhibit 99.2) for investors.
  • 3The disclosed financial results cover the fourth quarter and the entirety of the fiscal year 2023.
  • 4Both GAAP and non-GAAP financial information are referenced in the earnings release and presentation.
  • 5Reconciliations for non-GAAP financial measures are available within the furnished earnings press release.
  • 6The filing serves as a vehicle to disseminate the company's latest financial performance data and strategic initiatives.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce and provide access to Bristol Myers Squibb's financial results for the fourth quarter and full year ended December 31, 2023. It includes their earnings press release and a presentation.

The detailed financial results are found in the Earnings Press Release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2), which are furnished as part of this 8-K filing and incorporated by reference. The press release should be consulted for reconciliations of non-GAAP financial measures to GAAP.

This 8-K filing itself primarily reports on past financial results. Any forward-looking guidance or outlook would be contained within the furnished Earnings Press Release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2). Investors should review these documents for forward-looking statements.

According to the filing, the information furnished under Item 7.01 (which includes the press release and presentation) is not considered 'filed' for the purposes of Section 18 of the Exchange Act, nor is it subject to the liabilities of that section, unless specifically incorporated by reference into future filings.